← FDA DRUG APPROVALS
FDA ANDA · ANDA220269
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)
Sponsor: CREEKWOOD PHARMS
APPLICATION
ANDA220269
TYPE
ANDA
ORIGINAL APPROVAL
2026-04-07
LATEST ACTION
2026-04-07
ROUTE
ORAL
DOSAGE FORM
CAPSULE
MARKETING STATUS
Prescription
Products
NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)Prescription
NITROFURANTOIN 75MG, NITROFURANTOIN, MACROCRYSTALLINE 25MG · CAPSULE · ORAL
Approval history
2026-04-07UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.